Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment

Yasuto Yoneshima, Satoshi Morita, Masahiko Ando, Atsushi Nakamura, Shunichiro Iwasawa, Hiroshige Yoshioka, Yasuhiro Goto, Masafumi Takeshita, Toshiyuki Harada, Katsuya Hirano, Tetsuya Oguri, Masashi Kondo, Satoru Miura, Yukio Hosomi, Terufumi Kato, Toshio Kubo, Junji Kishimoto, Nobuyuki Yamamoto, Yoichi Nakanishi, Isamu Okamoto

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Renal impairment can affect treatment tolerability and outcome in individuals with cancer. We aimed to assess the safety and efficacy of nab-paclitaxel for previously treated patients with advanced non–small cell lung cancer (NSCLC) and renal impairment enrolled in a phase 3 trial of nab-paclitaxel vs. docetaxel. Patients and Methods: Previously treated NSCLC patients were randomly allocated (1:1) to receive docetaxel (60 mg/m²) on day 1 or nab-paclitaxel (100 mg/m²) on days 1, 8, and 15 of a 21-day cycle. Safety and efficacy outcomes of treatment were evaluated according to renal function. Results: Among the 503 patients enrolled in the phase 3 trial, 17.3% had moderate renal impairment (creatinine clearance of ≤50 mL/min, n = 49 for docetaxel and n = 38 for nab-paclitaxel) and 53.1% had mild renal impairment (creatinine clearance of >50 to ≤80 mL/min, n = 133 for docetaxel and n = 134 for nab-paclitaxel). For patients with renal impairment, the incidence of febrile neutropenia was lower in the nab-paclitaxel group than in the docetaxel group. The difference in treatment efficacy for nab-paclitaxel vs. docetaxel among patients with moderate or mild renal impairment was similar to that among the overall study population. Conclusion: Nab-paclitaxel was found to be tolerable and beneficial for previously treated patients with advanced NSCLC and mild or moderate renal impairment.

Original languageEnglish
Pages (from-to)585-592
Number of pages8
JournalClinical Lung Cancer
Volume23
Issue number7
DOIs
Publication statusPublished - 11-2022

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment'. Together they form a unique fingerprint.

Cite this